212 绎 Vol.14 No.5 ScienceDirect 阴 元元 元元 / 99978 5 doi: 1.3969/j.issn.1674-3849.212.5.3 2 1 29 72.7% 21 27.1% 24.26% 1 [1] 1 2 21 7.85 [2] 1 29 21% 662 26 9.38 211 3.8 27.2% 1 212-3-26 212-1-19 元 UL16/9-Y4/CMS/WYT1/ICMS Key Techniques for Systematic Evaluation of Chinese Medicine MYRG28(Y2-L4)-ICMS11-WYT Pharmaceutical Key Technology Studies Based on System Pharmacology for Innovative Chinese Medicine 元元 Tel 853-83978538 E-mail haohu@umac.mo Tel: 853-83974691 E-mail: ytwang@umac.mo 1958
绎 HDM 9 21 24.17% 4 33 7 211 1 8 8 211 1 2 5 4% 211 3.73 21 41% 1 2 211 2.68 25% 2 5 23 3 1 21 (%) ( ) (%) 1 11.36 7.85 21 2 1.28 7.1 22 3 7.18 4.96 7 4 5.43 3.75 22 5 4.67 3.22 15 6 3.88 2.68 24 F. Hoffmann-La Roche Ltd (SW) 7 3.27 2.25 64 8 3.13 2.16 1 16 2 211 (%) ( ) (%) 1 12.1 3.73 41 2 8.7 2.68 25 3 7.81 2.41 12 4 6.37 1.96-3 5 5.93 1.82 1 6 3.83 1.18 26 7 3.39 1.4 115 8 3.29 1.1 26 9.8.238-2 1.5.149-2 47.28 14.583 9 1959
212 绎 Vol.14 No.5 Rg 1 Re Rf Rb 1 [3] [4] [4~1] 1999 [11] [12] Rg 1 Re Rb 1 [13] [14,15] 35 5 [16~18] 3.8 45 3 45% 26 4 25 21.3 35 2 3 16.9 [19] 25 15 13.6 26% 24% 22% 2 9.38 19% 1 15 1 [2] 5 5 26 27 28 29 21 211 1 26~211 9 14 12 1 1.65 1.82 1.96 8 1.37 2.1 2.41 [21] 1.24 1.73 6 2.15.98 1.38 1.77 2.68 1.14 4 1.33.58 2.14.58.93 1.98 1.54.84 2 1.25 3.73 [22].92.83 1.37 1.82 2.31 2.65 26 27 28 29 21 211 27 2 26~211 5 9 196
绎 - [23] [4,7,14] 5 [24,25] 5 4% 26~211 5 25% 1. 21. :, 21, 1-11-14, 1-15-14. 2.. :, 25 颐 13~14. 3,,,. UPLC-MS/MS 5., 211, 46(4) 颐 297~299. 4,.., 29, 28(5) 颐 625~626. 5,. 3., 29, 4(3) 颐 35~36. 6,,,. FLAG., 211, 36(22) 颐 327~329. 7,. FORFIRI 3., 211,(9) 颐 52~53. 8. OLF., 211, 8(9) 颐 35. 9,.., 211 5(21) 颐 59~6. 1.., 211, 9(28) 颐 3~31. 11,,,.., 29, 11(8) 颐 19~22. 12,,.., 29, 3(17) 颐 122~123. 13,,,. RP-HPLC-ELSD 5., 211, 36(6) 颐 76~78. 14,,,.., 21, 38(1) 颐 123~127. 15,,.., 21, 4(2) 颐 73~75. 16,,. FOLFOX., 211, 9(27) 颐 11~13. 17,.., 21, 18 (12) 颐 1791~1792. 18,. 35., 28, 1(7) 颐 84. 19,,,.., 211, 36(6) 颐 666~671. 2,,.., 21, 4(6) 颐 33~332. 21,,,. 19., 21, 33(1) 颐 1671~1674. 22,.., 211, 1961
212 绎 Vol.14 No.5 23(1) 颐 143~144. 23,,,.., 211 39(3) 颐 19~22. 24 Song G, Luo Q, Qin J, et al. Effects of oxymatrine on proliferation and apoptosis in human hepatoma cells. Colloids Surf B Biointer 原 faces, 26, 48(1) 颐 1~5. 25 Huang WW, Ko SW, Tsai HY, et al. Cantharidin induces G2/M phase arrest and apoptosis in human colorectal cancer colo 25 cells through inhibition of CDK1 activity and caspase -dependent signaling pathways. Int J Oncol, 211, 38(4) 颐 167~173. Analysis of Anti-cancer Traditional Chinese Medicine Injections Based on Market Performance Lai Yunfeng 1, 2,LuJinjian 1, 2, Chen Xiuping 1, 2,HuHao 1, 2,WangYitao 1, 2 (1. State Key Laboratory of Quality Research in Chinese Medicine, Macao SAR, China, 99978; 2. Institute of Chinese Medical Sciences, University of Macau, Macao SAR, China, 99978) Abstract: Traditional Chinese medicine injections (TCMIs) have played vital roles in the treatment of cancer, cardiovascular diseases, virus and so on. This article analyzed the market of anti-cancer TCMIs in China, with special emphasis on Kang'ai injection, Shenqifuzheng injection, Aidi injection, Lentinan injection and Fufang Kushen injection which presented excellent market performances. An analysis on the technical features and clini 鄄 cal applications of these five anti -cancer TCMIs was also conducted. Finally, we pointed out constraints and possible solutions to the development of anti-cancer TCMIs. Keywords: Traditional Chinese medicine injection, anti-cancer, Chinese market 1962